Tag Archives: CT-0508

Thoughts on AstraZeneca’s Cell Therapy Pipeline

On Monday, January 16, AstraZeneca (AZ) announced (press release) the completion of Neogene Therapeutics’ acquisition for developing TCR-T therapies in solid tumors. Moreover, during JPM 2023, AZ introduced (presentation) AZD5851 (GPC3 armored CAR-T), its first official cell therapy program. Below, Celltelligence provides insights on AstraZeneca’s increasing interest in cell therapies, while discussing the potential of its innovative cell therapy pipeline.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Fate Tx and Carisma Present Clinical Updates in Liquid and Solid Tumors; SITC 2022 Analysis 2

SITC 2022 Analysis 2: Fate Tx and Carisma presented clinical updates from their novel cell therapies in liquid and solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Adaptimmune and GSK Present Updated Results from Afami-cel and Lete-cel ; CARsgen’s CT041 Demonstrates Clinical Efficacy in Gastric Cancer; First Clinical Data from Carisma’s CT-0508; ASCO 2022 Final Analysis

ASCO 2022 Final Analysis: Adaptimmune, GSK, CARsgen, and Carisma presented clinical updates from their novel cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Carisma’s CT-0508 (HER2 CAR-Macrophage) Receives Fast Track Designation From the FDA

On Wednesday, September 22, Carisma announced (press release) that the FDA has granted Fast Track designation to CT-0508 (HER2-targeting CAR-Macrophage) for HER2-overexpressing solid tumors. Below, Celltelligence provides insights on how CT-0508 could benefit from Fast Track designation, while discussing the potential advantages of CAR-Macrophages (CAR-M).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Switchable CAR-T Updates from Arcellx, GEMoaB, and AbClon; Carisma Therapeutics Presents Their CAR-Macrophage and CAR-Monocyte Programs; AACR 2021 Day 4

On the fourth day of AACR 2021 Week I, several key clinical / preclinical updates were presented from GEMoaB, Arcellx, AbClon, and Carisma Therapeutics. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.